Companies / Deals
AkzoNobel Says Two Sales Are the Only Remedies Regulators Want for the $25 Billion Axalta Merger
Chief Executive Greg Poux-Guillaume says no regulator has asked for anything beyond the two divestitures, as the companies aim at approval in the United States, Phase 1 clearance in Europe and a closing in early 2027.